课题基金 / 基金详情

"CELLBLOKS" - A novel 3-D liver model platform to predict human drug-induced liver injury (DILI)

"CELLBLOKS" - A novel 3-D liver model platform to predict human drug-induced liver injury (DILI)
“CELLBLOKS”——预测人类药物性肝损伤 (DILI) 的新型 3D 肝脏模型平台
批准号:
104432
负责人:
金额:
$8.88万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
"Drug-induced liver injury (DILI) is one of the leading cause of drug failure during development as well as number one cause of post-market drug withdrawal. There is a need for a more predictive tools to assess liver toxicity risks early in drug discovery. Human cell based laboratory models for safety screening are increasingly being developed as alternative methods to animal testing.Cell culture involves the growth of living cells in laboratory conditions without using animals in order to gain better understanding of body function, disease or to develop new drugs. Conventionally, cells are grown in 2-D glass or plastic surfaces such as Petri-dishes and plates.Researchers across many sectors, including pharmaceutical industry, research organisations and universities apply conventional cell culture for the growth and testing of mammalian cells. Cell culture has played a vital role in many life science discoveries such as the development of new drugs or vaccines. However, the results often lack efficiency as cell growth is constrained within the available 2-D surface when compared to true three-dimensional (3-D) environments of living tissue.ReVivoCell Ltd is developing a novel cell culture platform, that can better simulate the function of the liver in an _in-vitro_ setting. Existing 3-D cell culture technologies lack liver specific functionality, are expensive, difficult to use and are not easily adaptable for different experiments and cell types.This technology would potentially increase the success rate of developing new treatments and reduce the reliance on animal testing. The objective of this project is to assess the feasibility of a newly developed 3-D cell culture platform to mimmic liver-specific microenvironment. ReVivoCell's invention will provide a reliable, fast and cost effective device that could be used worldwide."
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: